Acquired Hemophilia - Symptoms, Causes, Treatment & Prevention

```html

Overview

Acquired hemophilia (also called acquired factor VIII inhibitor disease) is a rare bleeding disorder in which the immune system produces antibodies (inhibitors) that neutralize clotting factor VIII, a protein essential for normal blood coagulation. Unlike the inherited forms of hemophilia A and B, which are present from birth, acquired hemophilia develops later in life in individuals who previously had normal clotting function.

• Who it affects: Adults over 60 years old are most commonly affected, but it can also occur in younger adults and, rarely, in children.
• Incidence & prevalence: The disease is very uncommon, with an estimated incidence of 1–1.5 cases per million people per year worldwide (Mayo Clinic Proceedings, 2012). In the United States, roughly 150‑200 new cases are diagnosed each year.
• Prognosis: With prompt diagnosis and appropriate therapy, most patients achieve remission. However, mortality can reach 20 % in severe, untreated cases because of uncontrolled bleeding (CDC).

Symptoms

Symptoms of acquired hemophilia arise from spontaneous or trauma‑related bleeding and can vary widely in severity. The bleeding pattern frequently differs from that of congenital hemophilia, with more frequent involvement of skin and mucous membranes.

Common presenting signs

• Subcutaneous bruising (purpura): Large, painful bruises that appear without a clear cause, often on the abdomen, limbs, or trunk.
• Soft‑tissue hemorrhage: Deep muscle or fascial bleeding that can cause swelling, pain, and restricted movement.
• Mucosal bleeding: Nosebleeds (epistaxis), gum bleeding, or bleeding from the gastrointestinal tract.
• Hematuria: Blood in the urine, indicating urinary tract bleeding.
• Post‑operative or post‑traumatic bleeding: Excessive bleeding that continues after surgery or a minor injury despite normal initial hemostasis.
• Hemarthrosis (joint bleed): Much less common than in congenital hemophilia, but can still occur.

Red‑flag symptoms that suggest severe disease

• Rapidly expanding hematoma, especially in the neck or airway.
• Intracranial hemorrhage: severe headache, vomiting, altered consciousness.
• Massive gastrointestinal bleeding: melena or hematochezia with hemodynamic instability.
• Severe anemia with a sudden drop in hemoglobin.

Causes and Risk Factors

Acquired hemophilia is an autoimmune phenomenon. In most cases, the exact trigger cannot be identified, but several associations have been documented.

Underlying conditions

• Autoimmune diseases: Systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s syndrome.
• Malignancies: Particularly lymphoproliferative disorders (e.g., chronic lymphocytic leukemia, non‑Hodgkin lymphoma) and solid tumors (e.g., prostate, lung).
• Pregnancy and postpartum period: Approximately 10 % of cases occur during the third trimester or within 12 weeks after delivery (Cleveland Clinic).
• Medications: Certain drugs such as antibiotics (e.g., penicillins), sulfonamides, and checkpoint inhibitors have been implicated.

Risk factors

• Age > 60 years (most common age group).
• History of autoimmune disease or malignancy.
• Recent surgery, trauma, or infection that may stimulate an immune response.
• Genetic predisposition to autoimmunity (HLA‑DRB1*15, HLA‑DRB1*04 alleles).

Diagnosis

Because symptoms mimic other bleeding disorders, a high index of suspicion is required. Diagnosis relies on a combination of laboratory testing and clinical assessment.

Initial laboratory evaluation

1. Complete blood count (CBC): May show anemia secondary to blood loss.
2. Prothrombin time (PT): Usually normal because the extrinsic pathway is intact.
3. APTT (activated partial thromboplastin time): Prolonged in > 90 % of cases; reflects intrinsic pathway dysfunction.

Specific coagulation studies

• Mixing study: Patient plasma is mixed 1:1 with normal plasma. Failure of the APTT to correct suggests the presence of an inhibitor.
• Factor VIII activity assay: Quantifies functional factor VIII; levels are typically < 50 % and often < 10 %.
• Bethesda assay (or Nijmegen-modified Bethesda): Measures inhibitor titer in Bethesda Units (BU). Titers < 5 BU are considered low; > 5 BU are high and usually require more aggressive therapy.

Additional work‑up

• Screen for underlying disorders: ANA, anti‑dsDNA, rheumatoid factor, serum protein electrophoresis, CT scans for occult malignancy.
• Pregnancy testing in women of childbearing age.

Diagnostic criteria (summary)

• Unexpected, unexplained bleeding.
• Isolated prolonged APTT that does not correct on mixing.
• Reduced factor VIII activity with a demonstrable inhibitor.

Treatment Options

Therapy has two parallel goals: (1) control active bleeding and (2) eradicate the inhibitor.

1. Hemostatic agents (stop bleeding)

Choice depends on inhibitor titer, severity of bleeding, and availability.

• Bypassing agents:
  • Activated prothrombin complex concentrate (aPCC; FEIBA®) – 50‑100 U/kg every 8‑12 h.
  • Recombinant activated factor VII (rFVIIa; e.g., eptacog alfa) – 90‑120 µg/kg every 2‑3 h.
  Both agents bypass factor VIII and are effective even with high‑titer inhibitors.
• Recombinant porcine factor VIII (rpFVIII; Obizur®): Can be used when inhibitor titers are low‑to‑moderate; dosing is 200 U/kg, with repeat dosing guided by factor VIII levels.
• Tranexamic acid or aminocaproic acid: Antifibrinolytics are adjuncts for mucosal bleeding, dental procedures, or minor trauma.

2. Immunosuppressive therapy (eradicate the inhibitor)

Most patients require a combination of steroids and additional agents.

• First‑line regimen: Prednisone 1 mg/kg/day (max 80 mg) for 3‑4 weeks, often combined with cyclophosphamide 1‑2 mg/kg/day.
• Second‑line agents (if no response after 2‑3 weeks):
  • Rituximab 375 mg/m² weekly for 4 weeks (anti‑CD20 monoclonal antibody).
  • Mycophenolate mofetil 1‑2 g/day.
  • Azathioprine 2 mg/kg/day.
• Supportive measures: Prophylactic antibiotics for patients on high‑dose steroids, bone‑protective agents (e.g., calcium/vitamin D, bisphosphonates) to counteract steroid‑induced osteoporosis.

3. Monitoring and follow‑up

• Check APTT, factor VIII activity, and inhibitor titers 1‑2 weeks after initiating immunosuppression.
• Adjust immunosuppressive regimen based on response and side‑effects.
• Long‑term surveillance for relapse (approximately 20 % relapse rate within 5 years).

4. Lifestyle and supportive care

• Maintain a balanced diet rich in protein and vitamin K.
• Avoid medications that impair platelet function (e.g., aspirin, NSAIDs) unless prescribed for another indication.
• Vaccinate against influenza, pneumococcus, and hepatitis B (especially if on immunosuppressants).

Living with Acquired Hemophilia

Because the disease can be unpredictable, patients benefit from practical strategies that reduce bleeding risk and improve quality of life.

Daily management tips

• Bleeding diary: Record any bruises, nosebleeds, gum bleeds, or joint pain. Note triggers and severity.
• Regular lab checks: Keep scheduled appointments for clotting studies, even if you feel well.
• Protective clothing: Wear padded sleeves or knee pads during activities that could cause blunt trauma.
• Oral hygiene: Use a soft‑bristled toothbrush and avoid floss that snaps; rinse with chlorhexidine if you have gum bleeding.
• Exercise: Low‑impact activities (walking, swimming, stationary cycling) improve muscle strength without high injury risk.
• Medication safety: Keep an up‑to‑date list of all drugs and supplements; inform every health‑care provider of your diagnosis.
• Emergency plan: Carry a medical alert card/bracelet stating “Acquired Hemophilia – factor VIII inhibitor – requires bypassing agents.”

Psychosocial support

Living with a rare bleeding disorder can cause anxiety and isolation. Consider joining patient advocacy groups such as the National Hemophilia Foundation or online forums. Counseling and mental‑health services are valuable, especially during periods of intensive immunosuppression.

Prevention

Because the condition is largely autoimmune, primary prevention is limited. However, risk reduction strategies include:

• Prompt treatment of infections and avoidance of unnecessary invasive procedures.
• Regular cancer screening appropriate for age and sex (e.g., colonoscopy, mammography), which may identify underlying malignancies early.
• Management of autoimmune diseases under specialist care to keep immune activation as low as possible.
• In pregnant women with a known history of autoimmune disease, close obstetric‑hematology collaboration to monitor for postpartum inhibitor development.

Complications

If left untreated or inadequately managed, acquired hemophilia can lead to serious, potentially life‑threatening complications.

• Life‑threatening hemorrhage: Intracranial, intra‑abdominal, or retroperitoneal bleeding can cause shock and death.
• Chronic anemia: Recurrent bleeding may necessitate frequent transfusions, leading to iron overload.
• Inhibitor‑related arthropathy: Repeated joint bleeds cause cartilage damage and reduced mobility.
• Infections: Immunosuppressive therapy increases susceptibility to bacterial, viral, and fungal infections.
• Thrombotic events: Rarely, bypassing agents (especially aPCC) can predispose to clot formation; monitoring for signs of deep‑vein thrombosis or pulmonary embolism is essential.
• Medication toxicity: Cyclophosphamide can cause bladder toxicity and secondary malignancies; long‑term steroids cause osteoporosis, hyperglycemia, and mood changes.

When to Seek Emergency Care

Key Take‑aways

• Acquired hemophilia is a rare, autoimmune‑mediated bleeding disorder most often seen in older adults.
• Presenting signs are usually unexpected bruising or soft‑tissue bleeding; laboratory clues include a prolonged APTT that does not correct with mixing.
• Rapid diagnosis and treatment with bypassing agents, coupled with immunosuppression to eradicate the inhibitor, dramatically improve survival.
• Long‑term follow‑up, patient education, and a clear emergency plan are essential for safe living.

```